There are 3161 resources available
1339P - Impact of KRAS, STK11, and KEAP1 co-mutations on survival outcome and response to chemoimmunotherapy in patients with metastatic NSCLC
Presenter: Utsav Joshi
Session: Poster session 05
1341P - Exploring the role of the gut microbiome on the efficacy of ipilimumab and nivolumab in advanced non-small cell lung cancer: A prospective observational study
Presenter: Yuki Katayama
Session: Poster session 05
1342P - The efficacy of pembrolizumab vs nivolumab plus ipilimumab in metastatic NSCLC in relation to PD-L1 and TMB status
Presenter: Walid Shalata
Session: Poster session 05
1343P - Adding histology-driven chemotherapy (ChT) to overcome primary resistance to first-line immunotherapy (ICI) in patients (pts) with advanced non-small cell lung cancer (aNSCLC) with PD-L1 ≥50%
Presenter: Andrea De Giglio
Session: Poster session 05
1344P - Plasma proteomics indicated predictive biomarkers for immuno-chemotherapy in stage IIIB-IV non-small cell lung cancer without EGFR/ALK alterations
Presenter: Zhihuang Hu
Session: Poster session 05
1346P - A population-level prognostic score model for early acquired resistance to frontline anti-PD-(L)1 therapy in metastatic non-small cell lung cancer (NSCLC)
Presenter: Joseph Murray
Session: Poster session 05
1347P - Efficacy and safety of immune checkpoint inhibitor rechallenge in advanced lung cancer: A multicenter, real-world study
Presenter: Zhou Jin
Session: Poster session 05
1348P - First-line (1L) nivolumab (N) + ipilimumab (I) with 2 cycles of platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): Results from an interim analysis of the German non-interventional study (NIS) FINN
Presenter: Jonas Kuon
Session: Poster session 05